Clinical Trial

Management of Shock in Children With SAM or Severe Underweight and Diarrhea

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths. The coexistence of sepsis and hypovolemic shock in children with severe acute malnutrition (SAM) having diarrhea is common. At Dhaka hospital of icddr,b, the death rate is as high as 40% and 69% in children with severe sepsis and septic shock respectively with co-morbidities such as severe malnutrition. The conventional management of SAM children with features of severe sepsis recommended by WHO includes administration of boluses of isotonic saline followed by blood transfusion in unresponsive cases with septic shock; whereas the Surviving Sepsis Campaign (SSC) guideline recommends vasoactive support. To date, no study has evaluated systematically the effects of inotrope(s) and vasopressor or blood transfusion in children with dehydrating diarrhea (for example, in cholera) and SAM having shock and unresponsive to WHO standard fluid therapy. This randomized trial will generate evidence whether inotrope and vasopressor or blood transfusion should be selected for severely malnourished children having hypotensive shock and who failed to respond to WHO standard fluid bolus.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-02-07; most recent amendment 2025-04-13.
Status change: Not Yet Recruiting → Recruiting 2021-12-11
Trial Details
NCT Number NCT04750070
Lead Sponsor International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators: University of British Columbia, Muhimbili University of Health and Allied Sciences
Conditions Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline, Dopamine
Enrollment 135 participants
Start Date 2021-08-17
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-16